Jakarta, 18 June 2025 – PT Darya-Varia Laboratoria Tbk (Darya-Varia or the Company) successfully held its Annual General Meeting of Shareholders (AGMS) this morning, June 18, 2025, at The St. Regis Jakarta Hotel. During the AGMS, the Company reported that Darya-Varia continues to demonstrate resilience and consistency amid global economic challenges and ongoing changes in the pharmaceutical industry. Throughout 2024, the Company continued strong growth across core product categories, consumer health, prescription, toll-manufacturing, and export, reflecting the effectiveness of its business strategy and operational robustness.

In 2024, Darya-Varia posted net revenue of Rp2.09 trillion, up 10% from Rp1.9 trillion in 2023, surpassing the Company’s initial 7% growth target. Gross profit grew to Rp214.6 billion, 7% growth from the same period last year. Net income also rose by 7% to Rp156.15 billion, supported by efficient cost structures, strategic product mix improvements, and optimized supply chains.

At this morning’s Annual General Meeting of Shareholders, shareholders approved the reappointment of Mr. Mariano John Lim Tan, Jr. as Commissioner and Mr. Sonny Kalona as Independent Commissioner, whose terms conclude at the close of this year’s Annual General Meeting. These reappointments are expected to ensure continuity and stability in oversight, supporting the Company’s long-term vision and shareholder interests. The Meeting also approved the appointment of Mr. Jose Luis H. Narvaez, succeeding Mr. Angelito Celso Corsame Racho, Jr. following his retirement, and Mr. Alexander S. Panlilio as new members of the Board of Directors. These appointments reflect the Company’s commitment to strengthening its executive leadership with highly qualified professionals to support continued growth and innovation.

Looking ahead to 2025, Darya-Varia will continue to pursue sustainable growth strategies across its core business pillars, each offering meaningful opportunities for development. Amid a new economic phase marked by global uncertainties and foreign exchange volatility, Darya-Varia remains optimistic about balanced growth under Indonesia’s new leadership. The company targets 6–8% revenue growth and 5–7% net income growth in 2025, with a portion of earnings reinvested in production upgrades and brand-building efforts. It also aims to maintain a debt-free capital structure, fully supported by strong equity and positive cash flows.

“2024 has been a year of strategic progress, marked by double-digit revenue growth, healthy free cash flow, and disciplined investment. These achievements reflect our continued commitment to product quality, operational excellence, and strategic agility. As we approach our 50th anniversary in 2026, we remain committed to our vision of building a healthier Indonesia, strengthening our core brands, advancing capacity, and delivering value to all stakeholders,” said dr. Ian Martin Wibawa Kloer, President Director of PT Darya-Varia Laboratoria Tbk.